Skip to main content
. 2020 Nov 12;10(11):e041989. doi: 10.1136/bmjopen-2020-041989

Table 3.

Risk factors for mortality in patients with COVID-19 receiving respiratory support

Variable Univariate Multivariate analysis
P value* P value* HR (95% CI)
Age, years <0.001 <0.001 1.054 (1.028 to 1.082)
Male (yes/no) 0.014
Comorbidities (yes/no)
 Hypertension 0.392
 Diabetes 0.001 0.002 2.226 (1.357 to 3.652)
 Chronic obstructive pulmonary disease 0.009
 Chronic kidney disease 0.841
 Chronic liver disease 0.226
ACE inhibitor/ARB use (yes/no) 0.871
Lymphocyte count, ×103/uL <0.001 0.005 0.999 (0.998 to 1.000)
Platelet count, ×109/L 0.087 0.069 0.997 (0.994 to 1.000)
C reactive protein, mg/L 0.584
Aspartate aminotransferase, U/L 0.050 0.033 1.002 (1.000 to 1.003)
Alanine aminotransferase, U/L 0.552
Total bilirubin, mg/dL 0.831
Alkaline phosphatase, U/L 0.725
Gamma glutamyl transferase, U/L 0.263
Serum albumin, g/dL 0.773
Prothrombin time, INR 0.444
Estimated glomerular filtration rate, mL/min/1.73 m2 0.002
SIRS on admission (yes/no) <0.001 0.074 1.968 (1.199 to 3.230)

*Calculated by Cox proportional hazards regression test.

ARB, angiotensin II receptor blocker; INR, international normalised ratio; SIRS, systemic inflammatory response syndrome.

HHS Vulnerability Disclosure